Nivolumab Combo Treats Advanced Esophageal Squamous-Cell Carcinoma
THURSDAY, Feb. 3, 2022 -- For patients with previously untreated, advanced esophageal squamous cell carcinoma, treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab results in significantly longer overall survival than chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Metastases Occur in About 2 Percent of Cutaneous SCCs
TUESDAY, Feb. 1, 2022 -- Metastases develop in about 2 percent of cutaneous squamous cell carcinomas (cSCCs), according to a study published in the February issue of the Journal of the American Academy of Dermatology.
Selin Tokez, from the Erasmus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2022 Category: Pharmaceuticals Source Type: news
What Is the Survival Rate of Squamous Cell Carcinoma of the Skin?
Title: What Is the Survival Rate of Squamous Cell Carcinoma of the Skin?Category: Diseases and ConditionsCreated: 1/19/2022 12:00:00 AMLast Editorial Review: 1/19/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 19, 2022 Category: Cancer & Oncology Source Type: news
Mystery of the environmental triggers for cancer deepens
Study shows that our knowledge of why tumours form is still inadequateScientists will have to rethink howenvironmental triggers allow tumours to form and develop, one of Britain ’s leading cancer experts warned last week. Michael Stratton, director of the Wellcome Sanger Institute, said recent results from an international cancer research study – which aimed to pinpoint environmental triggers involved in oeosophageal cancer – indicated current scientific understanding of tumour formation was inadequate.The research – on a type known as oesophageal squamous cell carcinoma – was aimed at uncovering why certain part...
Source: Guardian Unlimited Science - October 24, 2021 Category: Science Authors: Robin McKie Tags: Cancer research Medical research UK news Science Source Type: news
New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer.
The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma.
Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making it t...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
A Clinical and Biological Review of Keratoacanthoma A Clinical and Biological Review of Keratoacanthoma
Can keratoacanthomas be differentiated from cutaneous squamous cell carcinoma? This review compares the pathophysiology and clinical characteristics of the two, suggesting they are distinct entities.The British Journal of Dermatology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2021 Category: Surgery Tags: Dermatology Journal Article Source Type: news
New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Human Papillomavirus-Associated Head and Neck Cancer Human Papillomavirus-Associated Head and Neck Cancer
Review the epidemiology, screening, presentation, diagnosis, prognosis, and prevention of HPV-positive oropharyngeal squamous cell carcinoma, with a focus on the primary care provider ' s role.Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Guidance Issued for Preventing Cutaneous SCC in Solid Organ Recipients
WEDNESDAY, Sept. 1, 2021 -- In a consensus statement published online Sept. 1 in JAMA Dermatology, recommendations are presented for prevention strategies for cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2021 Category: Pharmaceuticals Source Type: news
Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cutaneous Beta - HPV May Up Risk for Cutaneous Squamous Cell Carcinoma
Beta - HPV detected in skin swabs may predict cuSCC risk, but no link seen for serologic evidence of past beta - HPV infection (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 11, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Infections, Internal Medicine, Oncology, Pathology, Journal, Source Type: news
Cutaneous Beta-HPV May Up Risk for Cutaneous Squamous Cell Carcinoma
WEDNESDAY, Aug. 11, 2021 -- Cutaneous beta-human papillomavirus (HPV) may predict development of cutaneous squamous cell carcinoma (cuSCC), according to a study published online July 15 in Cancer Research.
Dana E. Rollison, Ph.D., from the Moffitt... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 11, 2021 Category: Pharmaceuticals Source Type: news
US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective ...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news
US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective ...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news
